ClinicalTrials.gg
Not yet recruitingNCT07853599Updated Oct 2, 2026

Diode Laser Versus Conventional Frenectomy in Children

An interventional study of Diode Laser Frenectomy and Conventional Scalpel Frenectomy in Frenulum; Hypertrophy, Diode Laser and Frenectomy, sponsored by Yuzuncu Yil University. Not yet recruiting at 1 site in Turkey (Türkiye). Open to participants aged 8 Years to 12 Years. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by Yuzuncu Yil University · Not applicable, Interventional, and Treatment

How we know

Updated Oct 2, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
8 Years to 12 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Hypertrophy with a site in Turkey — 2 open to participants now, 4 under way, none of them phase 3. Hypertrophy · Turkey.

Started
2026
with 2 others
No phase
9 of 10
2 open now
Registered
10th of 10
by date
Lead sponsor
1 of 10
Yuzuncu Yil University

Among the 10 studies in Hypertrophy with a site in Turkey, this one is one of 3 that started in 2026, is one of 9 with no phase, and was the 10th registered.

Hypertrophy

140 studies on the registry are indexed under Hypertrophy; 23 are open to participants now.

Browse Hypertrophy studies →

Open to participants now

2 of the 10 studies in Hypertrophy with a site in Turkey are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 13 Hypertrophy studies recruiting now, 3 (23%) set no upper age limit and 7 (54%) stop at 75 or younger; none take children under 18; 9 take healthy volunteers.

This study: 8 Years to 12 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Hypertrophy with a site in Turkey, or all of them as a file.
02

Study summary

This prospective, randomized, open-label, parallel-group clinical trial aims to compare diode laser frenectomy with conventional scalpel frenectomy in children aged 8-12 years with a clinical indication for maxillary labial frenectomy. Participants will be randomly allocated in a 1:1 ratio to undergo either diode laser or conventional scalpel frenectomy. Postoperative pain, wound healing, analgesic requirement, feeding difficulty, and daily comfort will be evaluated during follow-up. Gingival crevicular fluid samples will be collected at baseline and on postoperative Days 3, 7, and 14 to assess local molecular changes associated with inflammation, tissue injury, wound healing, and periodontal-alveolar remodeling using RT-qPCR.

Read the detailed description

This study is a prospective, randomized, open-label, two-arm, parallel-group clinical trial designed to compare the postoperative clinical and local molecular responses following diode laser and conventional scalpel frenectomy in children.

Children aged 8-12 years with a clinical indication for maxillary labial frenectomy who meet the eligibility criteria will be randomly allocated in a 1:1 ratio to either the diode laser frenectomy group or the conventional scalpel frenectomy group using computer-generated randomization. Because the two surgical procedures are visibly and technically different, masking of the treating clinician and participants is not feasible.

Clinical evaluations will be performed at baseline and during postoperative follow-up. Postoperative pain will be assessed using a 0-10 Visual Analog Scale (VAS), and wound healing will be evaluated using the Landry, Turnbull and Howley Wound Healing Index. Analgesic requirement, feeding difficulty, daily comfort, and other clinical healing findings will also be recorded. Standardized intraoral photographs obtained during follow-up will provide supportive assessment of postoperative wound healing.

Gingival crevicular fluid samples will be collected from the gingival sulcus adjacent to the maxillary central incisors at baseline (Day 0) and on postoperative Days 3, 7, and 14. Two sterile paper points will be used at each sampling time point. Samples will be transferred to RNase-free tubes, transported under cold-chain conditions, and stored at -80°C until molecular analysis.

RNA isolation, complementary DNA synthesis, and RT-qPCR analyses will be performed to evaluate gene expression changes related to inflammation, tissue injury, wound healing, and local periodontal-alveolar remodeling. Planned molecular targets include IL1B, TNF, IL8, FGF2, TGFB1, an LDH metabolism-related target gene, and SOST. GAPDH and ACTB will be used as reference genes. SOST will be evaluated as a secondary exploratory marker of local periodontal-alveolar remodeling.

Changes in clinical and molecular outcomes will be evaluated over time and between treatment groups, including assessment of group, time, and group-by-time effects.

03

Conditions studied

  • Frenulum; Hypertrophy
  • Diode Laser
  • Frenectomy
  • RT-PCR

Browse trials for

Keywords

  • Frenectomy
  • Maxillary Labial Frenum
  • Inflammatory Biomarkers
04

Who can participate

Ages eligible
8 Years to 12 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Children aged 8-12 years.
  • Presence of a clinical indication for maxillary labial frenectomy.
  • Systemically healthy.
  • No previous frenulum surgery in the relevant region.
  • Ability to attend scheduled clinical follow-up and gingival crevicular fluid sampling visits.
  • Written provided by a parent or legal guardian.
  • Age-appropriate assent provided by the child.
  • Adequate cooperation to undergo the planned clinical procedures and gingival crevicular fluid sampling.

Exclusion criteria

Exclusion Criteria:

  • Presence of a systemic disease or condition that may affect wound healing or inflammatory responses.
  • Active local infection or inflammation in the relevant region.
  • Use of systemic antibiotics, anti-inflammatory drugs, or within the previous month.
  • Regular use of medications known to affect wound healing or inflammatory responses.
  • Inadequate cooperation preventing completion of the surgical procedure or gingival crevicular fluid sampling.
  • Absence of parental/legal guardian consent or child assent.
  • Inability to complete the scheduled follow-up and sampling visits.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Diode Laser Frenectomy

    Children aged 8-12 years assigned to this arm will undergo maxillary labial frenectomy using a diode laser. Clinical evaluations and gingival crevicular fluid sampling will be performed at baseline (Day 0) and on postoperative Days 3, 7, and 14.

    Procedure: Diode Laser Frenectomy

  • Active comparator
    Conventional Scalpel Frenectomy

    Children aged 8-12 years assigned to this arm will undergo maxillary labial frenectomy using a conventional surgical scalpel. Clinical evaluations and gingival crevicular fluid sampling will be performed at baseline (Day 0) and on postoperative Days 3, 7, and 14.

    Procedure: Conventional Scalpel Frenectomy

Interventions

  • ProcedureDiode Laser Frenectomy

    Maxillary labial frenectomy will be performed using a Woodpecker LX16 Plus diode laser under standardized clinical conditions. The procedure will be carried out by the Department of Periodontology. Laser parameters, including wavelength, power, operating mode, fiber diameter, and application technique, will be standardized according to the final study protocol.

  • ProcedureConventional Scalpel Frenectomy

    Maxillary labial frenectomy will be performed using a conventional surgical scalpel under standardized clinical conditions. The procedure will be carried out by the Department of Periodontology according to the study protocol.

06

What researchers measure

Primary outcomes

  1. Relative IL1B Gene Expression in Gingival Crevicular Fluid

    Relative IL1B gene expression in gingival crevicular fluid will be quantified using RT-qPCR. Expression levels will be normalized using GAPDH and ACTB as reference genes. Changes over time and differences between the diode laser and conventional scalpel frenectomy groups will be evaluated.

    Time frame: Baseline (Day 0) and postoperative Days 3, 7, and 14

  2. Relative TNF Gene Expression in Gingival Crevicular Fluid

    Relative TNF gene expression in gingival crevicular fluid will be quantified using RT-qPCR. Expression levels will be normalized using GAPDH and ACTB as reference genes. Changes over time and differences between the diode laser and conventional scalpel frenectomy groups will be evaluated.

    Time frame: Baseline (Day 0) and postoperative Days 3, 7, and 14

  3. Relative IL8 Gene Expression in Gingival Crevicular Fluid

    Relative IL8 gene expression in gingival crevicular fluid will be quantified using RT-qPCR. Expression levels will be normalized using GAPDH and ACTB as reference genes. Changes over time and differences between the diode laser and conventional scalpel frenectomy groups will be evaluated.

    Time frame: Baseline (Day 0) and postoperative Days 3, 7, and 14

  4. Relative FGF2 Gene Expression in Gingival Crevicular Fluid

    Relative FGF2 gene expression in gingival crevicular fluid will be quantified using RT-qPCR. Expression levels will be normalized using GAPDH and ACTB as reference genes. Changes over time and differences between the diode laser and conventional scalpel frenectomy groups will be evaluated.

    Time frame: Baseline (Day 0) and postoperative Days 3, 7, and 14

  5. Relative TGFB1 Gene Expression in Gingival Crevicular Fluid

    Relative TGFB1 gene expression in gingival crevicular fluid will be quantified using RT-qPCR. Expression levels will be normalized using GAPDH and ACTB as reference genes. Changes over time and differences between the diode laser and conventional scalpel frenectomy groups will be evaluated.

    Time frame: Baseline (Day 0) and postoperative Days 3, 7, and 14

  6. Relative LDHA Gene Expression in Gingival Crevicular Fluid

    Relative LDHA gene expression in gingival crevicular fluid will be quantified using RT-qPCR. Expression levels will be normalized using GAPDH and ACTB as reference genes. Changes over time and differences between the diode laser and conventional scalpel frenectomy groups will be evaluated.

    Time frame: Baseline (Day 0) and postoperative Days 3, 7, and 14

  7. Postoperative Wound Healing Assessed Using the Landry, Turnbull and Howley Wound Healing Index

    Postoperative wound healing will be evaluated using the Landry, Turnbull and Howley Wound Healing Index. Healing will be scored from 1 (very poor healing) to 5 (excellent healing). Scores will be compared between treatment groups and across postoperative follow-up time points.

    Time frame: Postoperative Days 3, 7, and 14

  8. Postoperative Pain Intensity Assessed Using the Visual Analog Scale

    Postoperative pain intensity will be assessed using a 0-10 Visual Analog Scale (VAS), where 0 indicates no pain and 10 indicates the worst imaginable pain. VAS scores will be compared between treatment groups and across postoperative follow-up time points.

    Time frame: Postoperative Days 3, 7, and 14

Secondary outcomes

  1. Relative SOST Gene Expression in Gingival Crevicular Fluid

    Relative SOST gene expression in gingival crevicular fluid will be quantified using RT-qPCR. Expression levels will be normalized using GAPDH and ACTB as reference genes. SOST will be evaluated as an exploratory marker of local periodontal-alveolar remodeling following frenectomy.

    Time frame: Baseline (Day 0) and postoperative Days 3, 7, and 14

  2. Postoperative Analgesic Use

    Postoperative analgesic use will be recorded during follow-up. The number of analgesic doses taken by each participant will be documented and compared between the diode laser and conventional scalpel frenectomy groups.

    Time frame: Postoperative Days 3, 7, and 14

  3. Postoperative Feeding Difficulty

    Feeding difficulty will be assessed using a 0-10 numerical rating scale, where 0 indicates no difficulty with eating and 10 indicates the greatest possible difficulty. Scores will be compared between the diode laser and conventional scalpel frenectomy groups.

    Time frame: Postoperative Days 3, 7, and 14

  4. Postoperative Daily Comfort

    Daily comfort will be assessed using a 0-10 numerical rating scale, where 0 indicates extreme discomfort and 10 indicates complete comfort. Scores will be compared between the diode laser and conventional scalpel frenectomy groups.

    Time frame: Postoperative Days 3, 7, and 14

07

Study locations

1 site
  • Van Yüzüncü Yıl University Faculty of Dentistry
    Van, Turkey (Türkiye)
08

References and documents

Individual participant data

Plan to share: No — Individual participant data are not planned to be shared because the study involves pediatric participants and molecular biomarker data. De-identified aggregate results will be reported in scientific publications in accordance with applicable ethical and institutional requirements.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Oct 2027, 11 months later.

Of 65 non-industry interventional studies with no phase under Hypertrophy, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 22. This study's planned 11 months is below that.

Counting every sponsor, half of 78 studies reached it within 13 months; a quarter within 6 and three quarters within 22.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 26, 2026
First posted
Oct 2, 2026
StartEst.
Nov 1, 2026
Primary completionEst.
Oct 14, 2027
CompletionEst.
Nov 30, 2027
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07853599
Lead sponsor
Yuzuncu Yil University
Responsible party
Burçin AVCI (Assistant Professor, Yuzuncu Yil University) — Principal investigator
First posted
Oct 2, 2026
Start date
Nov 1, 2026 (estimated)
Primary completion
Oct 14, 2027 (estimated)
Completion
Nov 30, 2027 (estimated)
Last update
Oct 2, 2026

Study contacts

Burçin AVCI, DDS
Contact
burcinavci@yyu.edu.tr
+905359558140
Burçin AVCI
principal investigator · Van Yüzüncü Yıl Universityc

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion